tau 免疫疗法治疗阿尔茨海默病和相关 tau 病：进展和潜在陷阱。
Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.
机构信息
Departments of Neuroscience and Physiology, and Psychiatry, Neuroscience Institute, New York University School of Medicine, New York, NY, USA.
出版信息
J Alzheimers Dis. 2018;64(s1):S555-S565. doi: 10.3233/JAD-179937.
Abstract
Tau immunotherapies have now advanced from proof-of-concept studies to Phase II clinical trials. This review briefly outlines developments in the field and discusses how these therapies may work, which involves multiple variables that are connected in complex ways. These various factors are likely to define therapeutic success in humans and have not been thoroughly investigated, at least based on published reports.
摘要
tau 免疫疗法现在已经从概念验证研究推进到了 II 期临床试验。本文简要概述了该领域的发展，并讨论了这些疗法的作用机制，其中涉及多个以复杂方式相互关联的变量。这些各种因素可能会定义 tau 免疫疗法在人类中的治疗成功，而且至少根据已发表的报告，这些因素尚未得到彻底研究。
相似文献
1
Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.tau 免疫疗法治疗阿尔茨海默病和相关 tau 病：进展和潜在陷阱。
J Alzheimers Dis. 2018;64(s1):S555-S565. doi: 10.3233/JAD-179937.
2
Tau immunotherapies: Lessons learned, current status and future considerations.tau 免疫疗法：经验教训、现状和未来思考。
Neuropharmacology. 2020 Sep 15;175:108104. doi: 10.1016/j.neuropharm.2020.108104. Epub 2020 Apr 28.
3
Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.用于阿尔茨海默病和相关 tau 病的 Tau 免疫疗法：临床试验现状和临床前研究的见解。
J Alzheimers Dis. 2024;101(s1):S129-S140. doi: 10.3233/JAD-231238.
4
Tau immunotherapy for Alzheimer's disease.针对阿尔茨海默病的 Tau 免疫疗法。
Trends Mol Med. 2015 Jun;21(6):394-402. doi: 10.1016/j.molmed.2015.03.003. Epub 2015 Apr 3.
5
Immunotherapy for tauopathies.针对 Tau 病的免疫疗法。
J Mol Neurosci. 2011 Nov;45(3):690-5. doi: 10.1007/s12031-011-9576-5. Epub 2011 Jul 8.
6
Current Status of Clinical Trials on Tau Immunotherapies.tau 免疫疗法的临床试验现状。
Drugs. 2021 Jul;81(10):1135-1152. doi: 10.1007/s40265-021-01546-6. Epub 2021 Jun 8.
7
Tau Immunotherapy.tau蛋白免疫疗法
Neurodegener Dis. 2016;16(1-2):34-8. doi: 10.1159/000440842. Epub 2015 Nov 10.
8
A walk through tau therapeutic strategies.穿越 tau 治疗策略的漫步。
Acta Neuropathol Commun. 2019 Feb 15;7(1):22. doi: 10.1186/s40478-019-0664-z.
9
Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.使用脂质体疫苗产生的新型磷酸化tau单克隆抗体，对构象性tau病表位的识别增强。
J Alzheimers Dis. 2017;56(2):585-599. doi: 10.3233/JAD-160695.
10
Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.靶向tau的被动免疫调节tau转基因小鼠的病理学特征。
J Neurochem. 2015 Jan;132(1):135-45. doi: 10.1111/jnc.12821. Epub 2014 Aug 1.
引用本文的文献
1
Inhibition of the GSK3β/Nav1.6 complex suppresses early-stage Alzheimer's hyperexcitability.抑制GSK3β/Nav1.6复合物可抑制早期阿尔茨海默病的过度兴奋。
Alzheimers Dement. 2025 Jul;21(7):e70507. doi: 10.1002/alz.70507.
2
Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.治疗阿尔茨海默病的新型治疗方法：综述
ACS Omega. 2025 Feb 3;10(6):5148-5171. doi: 10.1021/acsomega.4c05527. eCollection 2025 Feb 18.
3
Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve.神经学临床试验中的安全问题：一项美国食品药品监督管理局必须解决的挑战。
Biomedicines. 2024 Dec 22;12(12):2918. doi: 10.3390/biomedicines12122918.
4
Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease.治疗阿尔茨海默病的治疗方法的最新进展。
Molecules. 2024 Oct 30;29(21):5131. doi: 10.3390/molecules29215131.
5
Alzheimer's Disease Protein Targets: Comprehensive Review and Future Directions.阿尔茨海默病的蛋白质靶点：综述与未来方向
Curr Pharm Des. 2025;31(17):1347-1369. doi: 10.2174/0113816128334916241006195142.
6
Therapeutic Potential of Traditional Oriental Medicines in Targeting Tau Pathology: Insights from Cell-free and Cell-based Screening.传统东方药物靶向Tau病理的治疗潜力：来自无细胞和基于细胞筛选的见解
Curr Med Chem. 2025;32(9):1830-1845. doi: 10.2174/0109298673295901240311072440.
7
Untangling Tau: Molecular Insights into Neuroinflammation, Pathophysiology, and Emerging Immunotherapies.解析Tau蛋白：对神经炎症、病理生理学及新兴免疫疗法的分子见解
Curr Issues Mol Biol. 2023 Nov 2;45(11):8816-8839. doi: 10.3390/cimb45110553.
8
Tau-targeting therapies for Alzheimer disease: current status and future directions.针对阿尔茨海默病的靶向 Tau 治疗：现状与未来方向。
Nat Rev Neurol. 2023 Dec;19(12):715-736. doi: 10.1038/s41582-023-00883-2. Epub 2023 Oct 24.
9
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics.蛋白质聚集与神经退行性疾病：新型疗法的结构展望
Proteins. 2023 Aug 2. doi: 10.1002/prot.26561.
10
DNA Damage Increases Secreted Aβ40 and Aβ42 in Neuronal Progenitor Cells: Relevance to Alzheimer's Disease.DNA 损伤增加神经祖细胞中分泌的 Aβ40 和 Aβ42：与阿尔茨海默病的相关性。
J Alzheimers Dis. 2022;88(1):177-190. doi: 10.3233/JAD-220030.
本文引用的文献
1
Tau-targeting therapies for Alzheimer disease.针对阿尔茨海默病的 Tau 靶向治疗。
Nat Rev Neurol. 2018 Jul;14(7):399-415. doi: 10.1038/s41582-018-0013-z.
2
Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.预防性主动 Tau 免疫可导致 3xTg 小鼠中 Tau 和淀粉样蛋白-β 病理持续减少。
Sci Rep. 2017 Dec 6;7(1):17034. doi: 10.1038/s41598-017-17313-1.
3
Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.ABBV-8E12，一种人源化抗 Tau 抗体的临床前和临床开发，用于治疗阿尔茨海默病和其他 Tau 病。
J Prev Alzheimers Dis. 2017;4(4):236-241. doi: 10.14283/jpad.2017.36.
4
Emerging Diagnostic and Therapeutic Strategies for Tauopathies.tau蛋白病的新兴诊断与治疗策略
Curr Neurol Neurosci Rep. 2017 Sep;17(9):72. doi: 10.1007/s11910-017-0779-1.
5
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.靶向病理性tau蛋白N端的人源化单克隆抗体armanezumab：特性与治疗效力
Mol Neurodegener. 2017 May 5;12(1):33. doi: 10.1186/s13024-017-0172-1.
6
Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.给予抗tau抗体可增加转基因小鼠和tau蛋白病患者血浆中的tau蛋白水平。
Sci Transl Med. 2017 Apr 19;9(386). doi: 10.1126/scitranslmed.aal2029.
7
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.腺相关病毒介导的抗tau单链抗体片段表达可减少tau蛋白病小鼠模型中的tau蛋白积累。
J Exp Med. 2017 May 1;214(5):1227-1238. doi: 10.1084/jem.20162125. Epub 2017 Apr 17.
8
Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.靶向病理性tau蛋白的抗体可阻断体外培养的神经元对tau蛋白的摄取及中间神经元对tau蛋白的传播。
Am J Pathol. 2017 Jun;187(6):1399-1412. doi: 10.1016/j.ajpath.2017.01.022. Epub 2017 Apr 11.
9
Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.扫描超声与tau特异性单链抗体在tau转基因小鼠模型中的联合作用
Brain. 2017 May 1;140(5):1220-1230. doi: 10.1093/brain/awx052.
10
MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.基于MultiTEP平台的靶向tau蛋白N端的DNA表位疫苗可诱导强烈的免疫反应并减轻THY-Tau22小鼠的tau病理变化。
Vaccine. 2017 Apr 11;35(16):2015-2024. doi: 10.1016/j.vaccine.2017.03.020. Epub 2017 Mar 18.
Zotero 插件